Navigant Consulting Estimates the Worldwide Market for Rheumatoid Arthritis Will Increase to Nearly $15 Billion by 2009 , Study identifies eight new potential products to enter the market in the next five years.
With the worldwide prevalence of rheumatoid arthritis (RA) estimated at more than 20 million people in 2004 (based on U.S. Census Bureau data, World Health Organization statistics and epidemiology studies), Navigant Consulting’s (NYSE: NCI) Front Line Strategic Market Reports analysts have found that new research has led to the development of better diagnostic tests and the adoption of earlier, more aggressive treatment. In their recently concluded study entitled “Emerging Rheumatoid Arthritis Therapeutics: Physician Perspectives and Competitive Benchmarking Analysis of a High Growth Market,” the analysts have also determined that therapeutic revenue will expand substantially in this autoimmune disease segment as several novel products are poised to enter the U.S. and worldwide markets by 2009.
“In the next five years, there will be safer and more effective TNF (tumor necrosis factor) antagonists and other medications with different MOAs (modes of action) and greater use of MRI to assess hand joints,” said Kyle Strader, a rheumatologist and study participant based in Raleigh, N.C. According to Navigant Consulting’s research and analysis, the worldwide RA market will surpass $6.2 billion by the end of 2004 and increase to $14.8 billion by the end of 2009, driven by the introduction of eight new products and an aging population. Biological response modifiers (BRMs), the newest line of treatment for several autoimmune disorders, will continue to be the leading class in the RA category. Johnson & Johnson will remain the market leader with its current blockbuster therapy, infliximab (Remicade).
Subscribe to the World's Most Popular Newsletter (it's free!)
The drug’s competitors are Amgen’s etanercept (Enbrel) and anakinra (Kineret), as well as the recently introduced adalimumab (Humira) by Abbott Laboratories. These four BRMs will account for approximately three-quarters of the RA market by 2009. However, new RA treatments, including Roche’s atlizumab (Actemra) and rituximab (Rituxan, developed in collaboration with Biogen Idec and Genentech), will provide improved safety and efficacy profiles. “The discovery of new RA biomarkers will facilitate the development of novel diagnostic tests to detect the disease in its early stages,” said Charles Chang, Associate for Navigant Consulting’s Front Line Strategic Market Reports. “Additionally, increased and earlier use of biologic agents over the next five years will help limit disease progression in RA patients. The physicians we surveyed strongly expressed the need for improved medicines and outlined their criteria for prescribing one product over another. We feel our competitive benchmark analysis provides timely, in-depth information to help current and emerging drug manufacturers position their products for optimized profitability.”
Primary information for the study was gathered by conducting a web-based survey of a panel of 19 physician experts from across the country with extensive experience in treating RA. Supporting information was also collected through discussions with pharmaceutical company representatives and from secondary sources, including news releases, SEC filings, industry Web sites and scientific periodicals.
For additional details, complimentary PDF sample pages, or to order “Emerging Rheumatoid Arthritis Therapeutics: Physician Perspectives and Competitive Benchmarking Analysis of a High Growth Market,” please contact Anil Patel of Navigant Consulting at 650.525.1500 x135.
About Navigant Consulting Navigant Consulting, Inc. (NYSE: NCI) is a specialized independent consulting firm providing litigation, financial services, healthcare, energy and operational consulting services to government agencies, legal counsel and large companies facing the challenges of uncertainty, risk, distress and significant change. The Company focuses on industries undergoing substantial regulatory or structural change and on the issues driving these transformations. “Navigant” is a service mark of Navigant International, Inc. Navigant Consulting, Inc. (NCI) is not affiliated, associated, or in any way connected with Navigant International, Inc. and NCI’s use of “Navigant” is made under license from Navigant International, Inc. More information about Navigant Consulting can be found at www.navigantconsulting.com. Par L.J. le 01-04-2004